Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2017

01-08-2017 | Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Adenomatous Polyposis Syndromes: Familial Adenomatous Polyposis and MutYH-Associated Polyposis

Authors: Jean H. Ashburn, Matthew F. Kalady

Published in: Current Colorectal Cancer Reports | Issue 4/2017

Login to get access

Abstract

The purpose of this review is to provide an overview of the etiology, diagnosis, and clinical management of the two most common polyposis; change adenomatous to polyposis hereditary colorectal cancer syndromes, familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP). The syndromes are caused by inherited genetic variants in the APC and MutYH genes, respectively. Both syndromes carry significant increased risk of colorectal and extracolonic cancers. Intense surveillance is required to reduce this risk, and colectomy or proctocolectomy is frequently the ultimate form of colorectal cancer risk reduction. The colorectal phenotype and extracolonic manifestations continue to evolve as more is learned about the natural history of the diseases, particularly MAP.
Literature
1.
Béroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C. UMD (universal mutation database): a generic software to build and analyze locus-specific databases. Hum Mutat. 2000;15:86–94.CrossRefPubMed
2.
Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000;119:854–65.CrossRefPubMed
3.
Hes FJ, Nielsen M, Bik EC, Konvalinka D, Wijnen JT, Bakker E, et al. Somatic APC mosaicism: an underestimated cause of polyposis coli. Gut. 2008;57(1):71–6.CrossRefPubMed
4.
Arvantis ML, Jagelman DG, Fazio VW, et al. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 1990;33:639–42.CrossRef
5.
Rozen P, Samuel Z, Shomrat R, Legum C. Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. Gut. 1999;45:829–33.CrossRefPubMedPubMedCentral
6.
Bulow S, Bulow C, Nielson TF, et al. Centralizaton registration prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the Danish polyposis register. Scand J Gastroenterol. 1995;30:989–93.CrossRefPubMed
7.
•• Provenzale D, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G, et al. Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:1010–30. The most comprehensive clinical practice guidelines that guide the diagnosis, management, and surveillance of patients and family members with FAP.CrossRef
8.
Bussey HJR. Familial polyposis coli. Family studies, histopathology, diff erential diagnosis and results of treatment. Baltimore: Johns Hopkins University Press; 1975.
9.
Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology. 1991;100:1658–64.CrossRefPubMed
10.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.CrossRefPubMed
11.
Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857–60.CrossRefPubMedPubMedCentral
12.
Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–9.CrossRefPubMed
13.
Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054–9.CrossRefPubMedPubMedCentral
14.
Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, doubleblind trial. Cancer Prev Res (Phila). 2008;1:32–8.CrossRef
15.
• Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA. 2016;315:1266–75. A well-designed randomized trial reporting on the benefit of combining chemopreventive non-steroidal anti-inflammatory agents in FAP to reduce colorectal adenoma burden.CrossRefPubMedPubMedCentral
16.
• Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016;65:286–95. A well-designed randomized trial assessing the benefit of combining chemopreventive non-steroidal anti-inflammatory agents in FAP to reduce colorectal adenoma burden.CrossRefPubMed
17.
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. International CAPP consortium. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4:655–65.CrossRef
18.
Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2:50–6.CrossRefPubMedPubMedCentral
19.
West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010;59:918–25.CrossRefPubMed
20.
Church JM, McGannon BSW, Burke C, Clark B. Teenagers with familial adenomatous polyposis. Dis Colon Rectum. 2002;45:887–9.CrossRefPubMed
21.
Olsen KO, Juul S, Bulow S, et al. Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg. 2003;93:407–17.
22.
Bertario L, Russo A, Sala P, Eboli M, Giarola M, D'amico F, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95:102–7.CrossRefPubMed
23.
Church J, et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum. 2003;46:1175–81.CrossRefPubMed
24.
Church J, Burke C, McGannon E, Pastean O, Clark B. Predicting polyposis severity by proctoscopy: how reliable is it? Dis Colon Rectum. 2001;44:1249–54.CrossRefPubMed
25.
Slors FJ, van Zuijlen RP, van Dijk GJ. Sexual and bladder dysfunction after total mesorectal excision for benign diseases. Scand J Gastroenterol Suppl. 2000;232:48–5127.
26.
Larson DW, Davies MM, Dozois EJ. Sexual function, body image, and quality of life after laparoscopic and open ileal pouch-anal anastomosis. Dis Colon Rectum. 2008;51:392–6.CrossRefPubMed
27.
Remzi FH, Church JM, Bast J, Lavery IC, Strong SA, Hull TL, et al. Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. Dis Colon Rectum. 2001;44(11):1590–6.CrossRefPubMed
28.
•• Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am Coll Gastroenterol. 2015. The most comprehensive clinical practice guidelines that guide the diagnosis, management, and surveillance of patients and family members with FAP. These include the recommended approach to genetic testing and counseling in affected and at-risk patients.
29.
Groves CJ, Beveridge G, Swain DJ, Saunders BP, Talbot IC, Nicholls RJ, et al. Prevalence and morphology of pouch and ileal adenomas in familial adenomatous polyposis. Dis Colon Rectum. 2005;48:816–23.CrossRefPubMed
30.
Ooi BS, Remzi FH, Gramlich T, Church JM, Preen M, Fazio VW. Anal transition zone cancer after restorative proctocolectomy and ileoanal anastomosis in familial adenomatous polyposis: report of two cases. Dis Colon Rectum. 2003;46:1418–23.
31.
Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, Nagengast FM, van der Bijl J, van Dalsen AD, et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Int J Cancer. 2011b;129:256–61.CrossRefPubMed
32.
Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK. Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Color Dis. 2011;13:1222–9.CrossRef
33.
Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999;86:1185–9.CrossRefPubMed
34.
Xhaja X, Church J. Small bowel obstruction in patients with familial adenomatous polyposis related desmoid disease. Color Dis. 2013;15(12):1489–92.CrossRef
35.
Xhaja X, Church J. Enterocutaneous fistulae in familial adenomatous polyposis patients with abdominal desmoid disease. Color Dis. 2013;15(10):1238–42.CrossRef
36.
Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011a;129:256–61.CrossRefPubMed
37.
•• Church J, Xhaja X, LaGuardia L, O'Malley M, Burke C, Kalady M. Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum. 2015;58:444–8. An important descriptive study reporting that the location of the APC mutation does not predict the occurrence of desmoids in patients with FAP, but does predict severity.CrossRefPubMed
38.
Church J, Lynch C, Neary P, LaGuardia L, Elayi E. A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum. 2008;51(6):897–901.CrossRefPubMed
39.
Quintini C, Ward G, Shatnawei A, Xhaja X, Hashimoto K, Steiger E, et al. Mortality of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis: a single center review of 154 patients. Ann Surg. 2012;255(3):511–6.CrossRefPubMed
40.
• Quast DR, Schneider R, Burdzik E, Hoppe S, Möslein G. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Familial Cancer. 2016;15(1):31–40. An interesting observational study supporting the use of combination sulindac and anti-estrogen therapy for selected patients with desmoid disease.CrossRefPubMed
41.
Sturt NJ, Phillips RK, Clark SK. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;101(3):652.CrossRefPubMed
42.
Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet. 1989;2(8666):783–5.CrossRefPubMed
43.
Groves CJ, Saunders BP, Spigelman AD, et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut. 2002;50(5):636–41.CrossRefPubMedPubMedCentral
44.
O’Shea AM, Cleary SP, Croitoru MA, Kim H, Berk T, Monga N, et al. Pathological features of colorectal carcinomas in MYH-associated polyposis. Histopathology. 2008;53:184–94.CrossRefPubMedPubMedCentral
45.
•• Church J, Kravochuck S. The “studded” rectum: phenotypic evidence of MYH-associated polyposis. Dis Colon Rectum. 2016;59(6):565–9. A landmark observational study proposing that rectal ‘studding’ as a pathognomonic endoscopic clue for the diagnosis of MAP. Prior to this, no pathognomonic endoscopic clue had been suggested.CrossRefPubMed
46.
Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 2009;136:1251–60.CrossRefPubMed
47.
Balaguer F, Castellví-Bel S, Castells A, Andreu M, Muñoz J, Gisbert JP, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol. 2007;5:379–87.CrossRefPubMed
48.
Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GM, Halling KC, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology. 2004;127:9–16.CrossRefPubMed
49.
Church J, Heald B, Burke C, Kalady M. Understanding MYH-associated neoplasia. Dis Colon Rectum. 2012;55(3):359–62.CrossRefPubMed
50.
Castillejo A, Vargas G, Castillejo MI, Navarro M, Barberá VM, González S, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer. 2014;50:2241–50.CrossRefPubMed
51.
Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011;79:1–16.CrossRefPubMed
52.
Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ- line mutations in MYH. N Engl J Med. 2003;348:791–9.CrossRefPubMed
53.
Colon Cancer Family Registries. National cancer institute, division of cancer control and population sciences. 2016.
54.
•• Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014;146:1208–11. This study describes the colorectal cancer risk in MUTYH carriers and relative risks depending on the presence of colorectal cancer in family members.CrossRefPubMedPubMedCentral
55.
Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6):1976–85.CrossRefPubMed
56.
Giardiello FM, Krush AJ, Petersen GM, Booker SV, Kerr M, Tong LL, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. Gastroenterology. 1994;106:1542–7.CrossRefPubMed
Metadata
Title
Adenomatous Polyposis Syndromes: Familial Adenomatous Polyposis and MutYH-Associated Polyposis
Authors
Jean H. Ashburn
Matthew F. Kalady
Publication date
01-08-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0379-0

Other articles of this Issue 4/2017

Current Colorectal Cancer Reports 4/2017 Go to the issue

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Colonoscopy and Flexible Sigmoidoscopy in Colorectal Cancer Screening and Surveillance

Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Inflammation and Colorectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

The Role of CT Colonography as a Screening Tool for Colorectal Cancer

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Colorectal Cancer Surveillance: What Is the Optimal Frequency of Follow-up and Which Tools Best Predict Recurrence?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits